Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage

PV Licciardi; FM Russell; A Balloch; RL Burton; MH Nahm; G Gilbert; MLK Tang; EK Mulholland

Journal article

Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage

PV Licciardi, FM Russell, A Balloch, RL Burton, MH Nahm, G Gilbert, MLK Tang, EK Mulholland

Vaccine | ELSEVIER SCI LTD | Published : 2014

DOI: 10.1016/j.vaccine.2014.02.064

Abstract

The impact of prior nasopharyngeal carriage on serotype-specific IgG responses following immunization with pneumococcal conjugate vaccines (PCV) has recently been described. This report extends these findings to describe the attenuation of functional immune responses following 23-valent pneumococcal polysaccharide vaccination (PPS). We report the attenuation of immune responses following booster with the 23-valent pneumococcal polysaccharide vaccination (PPS) in infants with prior nasopharyngeal carriage of Streptococcus pneumoniae. Fijian infants who were part of a phase II randomized, controlled trial of reduced dose PCV7 schedules were the basis of this study. Pneumococcal carriage was de..

View full abstract

University of Melbourne Researchers

Fiona Russell Author

Mimi Tang Author

Related Projects (2)

A study to investigate alternative regimens for pneumococcal vaccination of infants in a developing country

Streptococcus pneumoniae (Pnc) is the leading vaccine preventable cause of serious infection in infants. The current Pnc conjugate vaccine i..

Appropriate pneumococcal vaccination in infants in Fiji

DESCRIPTION (provided by applicant): The Fiji Pneumococcal Project that has been funded by NIH has been designed to provide all the informat..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

Funding source: This work was supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID; 2 U01 AI052337-05), the Australian National Health and Medical Research Council (NHMRC grant no. 251648), and the Victorian Government's Operational Infrastructure Support Program. Pneumovax was kindly donated by CSL Biotherapies, Australia. P.V.L. is a recipient of an NHMRC Training Fellowship. M.H.N. is supported by National Institutes of Health contract AI-30021.